Cargando…

Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial

Iron deficiency commonly affects patients with chronic kidney disease and has an important burden in disease trajectory and quality of life; nonetheless current guidelines do not advocate treatment of iron-deficiency without anemia in this patient group. Concerns exist regarding the potential effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kassianides, Xenophon, Allgar, Victoria, Macdougall, Iain C., Kalra, Philip A., Bhandari, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046378/ https://www.ncbi.nlm.nih.gov/pubmed/35477731 http://dx.doi.org/10.1038/s41598-022-10717-8

Ejemplares similares

The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease—A Pooled Analysis
por: Kassianides, Xenophon, et al.
Publicado: (2022)

The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD
por: Kassianides, Xenophon, et al.
Publicado: (2023)

Correction to: Protocol and baseline data for a prospective open-label explorative randomized singlecenter comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2020)

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
por: Kassianides, Xenophon, et al.
Publicado: (2021)

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status
por: Bhandari, S., et al.
Publicado: (2021)

Safety of intravenous iron use in chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2016)

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
por: McDonagh, Theresa, et al.
Publicado: (2015)

Point-of-care testing technologies for the home in chronic kidney disease: a narrative review
por: Bodington, Richard, et al.
Publicado: (2021)

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions
por: Macdougall, Iain C
Publicado: (2017)

Rationale and design of a randomised trial of intravenous iron in patients with heart failure
por: Kalra, Paul R, et al.
Publicado: (2022)

Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease
por: Nuhu, Faisal, et al.
Publicado: (2019)

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
por: Kalra, Philip A, et al.
Publicado: (2016)

High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis
por: Petrie, Mark C, et al.
Publicado: (2021)

Factors Governing the Erythropoietic Response to Intravenous Iron Infusion in Patients with Chronic Kidney Disease: A Retrospective Cohort Study
por: Chukwu, Chukwuma A., et al.
Publicado: (2023)

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
por: Bhandari, Sunil, et al.
Publicado: (2015)

Special issue: iron therapy in patients with chronic kidney disease
por: Macdougall, Iain C
Publicado: (2017)

A Randomized Trial of Intravenous Iron Supplementation and Exercise on Exercise Capacity in Iron-Deficient Nonanemic Patients With CKD
por: Greenwood, Sharlene A., et al.
Publicado: (2023)

Intravenous Iron Therapy with Saccharated Iron Oxide
por: Deshmukh, P. L.
Publicado: (1952)

Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2019)

Treatment of anaemia in end-stage renal disease: A double-edged iron sword?
por: Chinnadurai, Rajkumar, et al.
Publicado: (2019)

Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials
por: Graham, Fraser J., et al.
Publicado: (2021)

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)

The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial
por: Greenwood, Sharlene A., et al.
Publicado: (2022)

The Role of Iron in Calciphylaxis—A Current Review
por: Wickens, Olivia, et al.
Publicado: (2022)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

Intravenous Irons: From Basic Science to Clinical Practice
por: Bhandari, Sunil, et al.
Publicado: (2018)

The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
por: Macdougall, Iain C., et al.
Publicado: (2014)

Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice
por: Richards, Toby, et al.
Publicado: (2021)

Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON‐IDA/NEPHRO trials
por: Wolf, Myles, et al.
Publicado: (2020)

NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2020)

Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk
por: Ganz, Tomas, et al.
Publicado: (2020)

Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice
por: Bhandari, Sunil
Publicado: (2011)

Intravenous iron supplementation in heart failure patients induces temporary endothelial dysfunction with release of endothelial microvesicles
por: Mause, Sebastian F., et al.
Publicado: (2023)

Intravenous Iron Technique Evaluation in Chronic Heart Failure With Iron Deficiency Anemia
por: Gosavi, Rohit, et al.
Publicado: (2023)

Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
por: Jankowska, Ewa A., et al.
Publicado: (2013)

Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy
por: Jairam, A., et al.
Publicado: (2010)

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
por: Macdougall, Iain C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vklqspk36kjjta3nmgf6qgr8pb